Skip to main content
. 2020 Oct 28;26(2):e316–e326. doi: 10.1002/onco.13552

Table 1.

Selective FGFR‐directed tyrosine kinase inhibitors

Agent Infigratinib (BGJ398) Pemigatinib (INCB054828) Derazantinib (ARQ 087) Futibatinib (TAS‐120) Erdafitinib (JNJ‐42756493) Rogaratinib (BAY 1163877) Debio 1347
Chemical structure graphic file with name ONCO-26-e316-g004.jpg graphic file with name ONCO-26-e316-g005.jpg graphic file with name ONCO-26-e316-g006.jpg graphic file with name ONCO-26-e316-g007.jpg graphic file with name ONCO-26-e316-g008.jpg graphic file with name ONCO-26-e316-g009.jpg graphic file with name ONCO-26-e316-g010.jpg
Company QED Incyte ArQule Taiho Janssen Bayer Debiopharm
Source [65] [66] [67] [68] [69] [70] [71]
IC50, nM
FGFR1 0.9 0.4 4.5 1.8 1.2 11.2 9.3
FGFR2 1.4 0.5 1.8 1.4 2.5 <1 7.6
FGFR3 0.9 1.2 4.5 1.6 3 19 22
FGFR4 60 30 34 3.7 5.7 201 —

Abbreviations: FGFR, fibroblast growth factor receptor; IC50, median inhibitory concentration.